circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Cantor Virtual Global Healthcare Conference
    Sep 27, 2021 3:20 PM EDT

    Cantor Virtual Global Healthcare Conference
    Sep 27, 2021 3:20 PM EDT
  • Webcast
    X Morgan Stanley 19th Annual Global Healthcare Conference
    Sep 14, 2021 11:45 AM EDT

    Morgan Stanley 19th Annual Global Healthcare Conference
    Sep 14, 2021 11:45 AM EDT
  • Webcast
    X H.C. Wainwright 23rd Annual Global Investment Conference
    Sep 13, 2021 12:00 PM EDT

    H.C. Wainwright 23rd Annual Global Investment Conference
    Sep 13, 2021 12:00 PM EDT
  • Webcast
    X HFSA Investor Call/Webcast
    Sep 13, 2021 8:30 AM EDT

    HFSA Investor Call/Webcast
    Sep 13, 2021 8:30 AM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten  Supporting Progression to Phase 3 Clinical Trial Additional Results from GALACTIC-HF Show Effect of Treatment with
Toggle Summary Cytokinetics to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in the following investor conferences in September: H.C.
Toggle Summary Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host a conference call and webcast on September 13, 2021 at 8:30 AM Eastern Time to discuss the full results from REDWOOD-HCM ( R andomized E valuation of D osing W ith
Toggle Summary Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2021 it granted stock options to purchase an aggregate of 113,600 shares of common stock to 10 new employees, whose employment commenced in August 2021 , as